Fereydoon Abedi Gaballu

Fereydoon Abedi Gaballu

Auto-generated profile, based on publicly available information

Fereydoon Abedi Gaballu

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in Applied Materials Today
Verified
Journal Article
Closed access
FAFereydoon Abedi-Gaballu
Fereydoon Abedi-Gaballu
GDGholamreza Dehghan
Gholamreza Dehghan
MGMaryam Ghaffari
Maryam Ghaffari
RYReza Yekta
Reza Yekta
SASoheil Abbaspour-Ravasjani
Soheil Abbaspour-Ravasjani
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

28 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
BMBehzad Mansoori
Behzad Mansoori
AMAli Mohammadi
Ali Mohammadi
FAFereydoon Abedi‐Gaballu
Fereydoon Abedi‐Gaballu
SASoheil Abbaspour-Ravasjani
Soheil Abbaspour-Ravasjani
MGMehri Ghasabi
Mehri Ghasabi
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

1 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
BMBehzad Mansoori
Behzad Mansoori
AMAli Mohammadi
Ali Mohammadi
ZAZahra Asadzadeh
Zahra Asadzadeh
SSSolmaz Shirjang
Solmaz Shirjang
MMMahsa Minouei
Mahsa Minouei
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

23 January 2015 in Pharmaceutical Biology
Verified
Journal Article
Closed access
FGFereydoon Abedi Gaballu
Fereydoon Abedi Gaballu
YGYousef Abedi Gaballu
Yousef Abedi Gaballu
OKOmid Moazenzade Khyavy
Omid Moazenzade Khyavy
AMAlireza Mardomi
Alireza Mardomi
KGKazem Ghahremanzadeh
Kazem Ghahremanzadeh
HMHiman Mamandy
Himan Mamandy
Several therapeutic effects such as antioxidant and blood glucose-lowering activities have been reported for Peganum harmala L (Zygophyllaceae) (PH) seeds, Rhus coriaria L (Anacardiaceae) (RC) fruits, and Urtica dioica L (Urticaceae) (UD) leaves. This study investigates the effects of a triplex mixture (1:1:1) of these medicinal plants on metabolic and histological parameters in diabetic rats. Aqueous extracts of PH, RC and UD were administered as either monotherapy or in combination at a final dose of 200 mg/kg to alloxan-induced diabetic rats by daily gavage. Biochemical parameters including blood glucose, liver function-related enzymes, lipid profile, and creatinine were estimated by spectrophotometric methods. Tissues from the liver and kidney stained with hematoxylin/eosin were histologically examined. The results obtained from the exposure groups were compared to either healthy or diabetic control groups. Compared with the diabetic control rats, all aqueous extracts (ED50 = 11.5 ± 2.57 mg/ml) led to significant decreases in the levels of ALP (1.39-2.23-fold, p < 0.05), low-density lipoprotein cholesterol (LDL-C) (1.79-3.26-fold, p < 0.05), and blood glucose (1.27-4.16-fold, p < 0.05). The serum concentrations of TG was decreased only by treatment with UD and triplex mixture (1.25- and 1.20-fold, respectively, p < 0.05). Among the studied parameters, alanine aminotransferase (ALT), LDL-C, TG, and creatinine recovered to healthy control levels after 4 weeks of treatment with the extract mixture. This study showed that PH, RC, and UD extracts, especially their combination, had significant antidiabetic, hypolipidemic, and liver and renal damage recovering effects.

11 May 2020 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
SSSolmaz Shirjang
Solmaz Shirjang
BMBehzad Mansoori
Behzad Mansoori
AMAli Mohammadi
Ali Mohammadi
NSNeda Shajari
Neda Shajari
Pascal DuijfPascal Duijf
Pascal Duijf
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
Purpose: Based on WHO report, colorectal cancer (CRC) is the second cause of death among patients with cancer worldwide. Dysregulation of miRNAs expressions has been demonstrated in different human cancers, especially CRC. Studies have shown that miR-330 could act as both TS-miR and/or oncomiR in different types of cancers. BACH1 is also identified as a transcription factor, which is involved in ontogenesis. In this study, we evaluated the CRC suppression via silencing of BACH1 by small silencer molecule called miR-330.Methods:Firstly, we analyzed the BACH1, miR-330-3p and miR-330-5p expressions according to the colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) project established from a patient of the colon and rectal cancer patients in The Cancer Genome Atlas (TCGA) database. The targeting of BACH1 via miR-330 in human CRC cells was evaluated by Vejnar bioinformatics methods, and confirmed by qRT-PCR and western blot analysis. Proliferation was performed by MTT assay. The MMP9, CXCR4, and VEGFR proteins were measured by western blotting.Results:The analysis of BACH1, miR-330-3p, and miR-330-5p expressions according to the COAD and READ projects showed that BACH1 was overexpressed, but miR-330-3p and miR330-5p were reduced in CRC tumors compared to normal controls. The miR-330 induction prevented proliferation of CRC cell by targeting BACH1 mRNA, which represses MMP9, C-X-C chemokine receptor type 4 (CXCR4), and vascular endothelial growth factor receptor (VEGFR) proteins expressions.Conclusion:Our results suggested that BACH1 is a potential target for miR-330 in CRC cells. The miR-330 induction inhibits CRC cells proliferation by suppressing BACH1 expression in posttranscriptional level. It was suggested that targeting of BACH1 via miRNA such as miR-330 could be a valid strategy in the field of CRC targeted therapy via modulating the oncogenic signaling pathway.